Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626158 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
A Phase 1 study of Pancreatic Cancer and Biliary Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT00626158: Completed Phase 1 study of Pancreatic Cancer and Biliary Cancer, sponsored by University of California, San Francisco.
NCT00626158 is a Phase 1 study of Pancreatic Cancer and Biliary Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 45 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626158, a Phase 1 study of Pancreatic Cancer and Biliary Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chemotherapy drugs used to treat pancreatic and biliary cancer. These two drugs used together are considered an acceptable standard of care for pancreatic and biliary cancers. However, in this study the dose and dosing schedule will be changed, in the hopes that the drugs will have more effect with fewer side effects than when given in the standard way.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG capecitabine
Study Locations (2)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Utah
- Huntsman Cancer Center, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT00626158 record still lists
NCT00626158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00626158 reports a single indexed study location in California, Utah.
Frequently Asked Questions
What is clinical trial NCT00626158 about?
NCT00626158 is a clinical study titled "Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers". The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chem...
What is the current status of trial NCT00626158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-02. Estimated completion is 2010-12.
What conditions does trial NCT00626158 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Biliary Cancer.
What interventions are being tested in trial NCT00626158?
The interventions under investigation include: gemcitabine (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00626158?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626158 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00626158's enrollment target sits among peer trials
45 162nd of 278 higher than 115 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03588975 · 45 participants · Phase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia